Activator protein-2 (AP-2) is a transcription factor that regulates proliferation and differentiation in mammalian cells and has been implicated in the acquisition of the metastatic phenotype in several types of cancer. Herein, we examine the role of AP-2a in colon cancer progression. We provide evidence for the lack of AP-2a expression in the late stages of colon cancer cells. Re-expression of the AP-2a gene in the AP-2a-negative SW480 colon cancer cells suppressed their tumorigenicity following orthotopic injection into the cecal wall of nude mice. The inhibition of tumor growth could be attributed to the increased expression of E-cadherin and decreased expression and activity of matrix-metalloproteinase-9 (MMP-9) in the transfected cells, as well as a substantial loss of their in vitro invasive properties. Conversely, targeting constitutive expression of AP-2a in AP-2-positive KM12C colon cancer cells with small interfering RNA resulted in an increase in their invasive potential, downregulation of E-cadherin and increased expression of MMP-9. In SW480 cells, re-expression of AP-2a resulted in a fourfold increase in the activity of E-cadherin promoter, and a 5-14-fold decrease in the activity of MMP-9 promoter, indicating transcriptional regulation of these genes by AP-2a. Chromatin immunoprecipitation assay showed that re-expressed AP-2a directly binds to the promoter of E-cadherin, where it has been previously reported to act as a transcriptional activator. Furthermore, chromatin immunoprecipitation assay revealed AP-2a binding to the MMP-9 promoter, which ensued by decreased binding of transcription factor Sp-1 and changes in the recruitment of transcription factors to a distal AP-1 element, thus, contributing to the overall downregulation of MMP-9 promoter activity. Collectively, our data provide evidence that AP-2a acts as a tumor suppressor gene in colon cancer.
Introduction
Colorectal cancer is the second leading cause of death and the fourth most commonly diagnosed cancer in the Western world including the US (Rozen, 2004) . Approximately one million cases of colorectal cancer were diagnosed worldwide during the year 2000 (Vainio and Miller, 2003) , and the incidence of new cases has risen each year since 1975 (Rozen, 2004) . The adenomacarcinoma sequence of gene mutations in colorectal cancer has been relatively well characterized (Boedefeld et al., 2003) ; nonetheless, a more clear understanding of the role and significance of both oncogenes and tumor suppressor genes involved are still needed. Activator protein-2 (AP-2) is a cell type-specific DNA-binding transcription factor family that has the ability to specifically regulate the expression of other genes in vertebrate organism. AP-2 is a family of different, yet closely related, proteins with a molecular weight around 50 kDa (Hilger-Eversheim et al., 2000) . AP-2 family members are expressed from different genes. Five different isoforms of AP-2, i.e., AP-2a, AP-2b, AP-2g, AP-2d and APe have been identified (Williams et al., 1988; Moser et al., 1995; Bosher et al., 1996; Zhao et al., 2001; Tummala et al., 2003) .
Accumulating evidence has established that AP-2 participates in many aspects of specific gene expression in mammals. AP-2 is one of the critical factors of neural gene expression (Mitchell et al., 1991) and various neural genes contain AP-2 binding sites in their regulatory regions. Loss of AP-2a expression has been associated with progression of melanoma , prostate cancer (Ruiz et al., 2004) and colorectal cancer (Ropponen et al., 1999 (Ropponen et al., , 2001 ). In addition, immunohistochemical studies of human melanoma, breast and colorectal cancer specimens have revealed that loss of AP-2a coincides with poor prognosis (Karjalainen et al., 1998; Ropponen et al., 1999; Pellikainen et al., 2004) . We have demonstrated previously that normal melanocytes and nonmetastatic melanoma cell lines express high levels of AP-2a. In contrast, highly metastatic melanoma cell lines do not express AP-2a. This tumor-suppressor-like role of AP-2a in melanoma is directly linked to its ability to regulate the expression of genes involved in adhesion, survival and invasion. For example, loss of AP-2a in metastatic melanoma causes deregulated expression of c-Kit (Huang et al. 1998) , Melanoma Cellular Adhesion Molecule (MCAM/MUC18) (Jean et al., 1988) , Thrombin Receptor (PAR-1) and Matrix Metalloproteinase-2 (MMP-2) (Gershenwald et al., 2001 ) genes, inducing resistance to apoptosis, adhesion to endothelial cells and increased angiogenesis and invasion, thus promoting the metastatic phenotype (Bar-Eli, 2001 ). Furthermore, transfection of highly metastatic melanoma cells with full-length AP-2a greatly reduces their tumorigenicity and metastatic potential in nude mice (Huang et al., 1998) . In addition, we recently showed that loss of AP-2a contributed to enhance tumorigenicity of prostate cancer cells via upregulation of the VEGF gene (Ruiz et al., 2004) . Transfection of AP-2a into hepatoblastoma and colon adenocarcinoma cell lines, which lack endogenous AP-2a expression, has resulted in negative cell cycle control and cell growth inhibition in vitro (Pellikainen et al., 2003) . Immunohistochemical studies have shown that downregulated cytoplasmic AP-2a expression was consistently seen in high grade and advanced Duke's stage tumors (Ropponen et al., 2001 ). In addition, low cytoplasmic AP-2a expression was seen in high-grade carcinomas (Ropponen et al., 2001 ), corroborating previous reports in which low AP-2a expression was associated with higher tumor malignancy and poor survival (Karjalainen et al., 1998; Ropponen et al., 1999; Pellikainen et al., 2003) . However, the exact mechanism by which loss of AP-2a contributes to colon cancer progression is yet to be investigated.
This study intends to examine the role of AP-2a in colon cancer cells. Re-expression of AP-2a in AP-2a-negative SW480 cells resulted in the expression of E-cadherin and downregulation of the MMP-9 expression, as well as dramatic loss of cellular invasive potential in vitro. We further demonstrate for the first time that transfection of AP-2a in SW480 colon cancer cells abolished colon tumor development following orthotopic cecal injection in nude mice, suggesting that AP-2a may act as a tumor suppressor gene in colon cancer.
Results
Transfection with AP-2a abolished in vivo growth of colon cancer cells in orthotopic animal model In the present study, we aimed to assess the role of the AP-2a transcription factor in colon cancer tumor growth. To that end, we analyzed several of colon cancer cell lines, i.e., KM12C, KM12-L4, KM12SM, SW480 and SW620 for the expression of AP-2a. Reverse transcription-polymerase chain reaction (RT-PCR) analysis (Figure 1 ) has revealed that the three cell lines KM12SM, SW480 and SW620 do not transcribe the AP-2a mRNA (lanes 3 and 5), while the cell lines KM12C and KM12L4 express low levels of AP-2a mRNA (lanes 1 and 2). As a positive control, we used the MCF7 nonmetastatic breast cancer cell line, known to express high levels of AP-2a (Figure 1, lane 6) . Lack of AP-2a protein expression in SW480 was confirmed by Western blot analysis ( Figure 2b , lane 2). Interestingly enough, among the KM12 cell lines tested, lack of AP-2a expression was observed in the KM12SM cell line that was established after selection of cells metastasizing into the cecum of nude mice (Morikawa et al., 1998) To determine whether the AP-2a in the transfected cells is functional, we next analyzed the ability of nuclear extracts from the transfected cells to bind to a consensus AP-2 binding DNA oligonucleotide in an electrophoretic mobility shift assay (EMSA). As shown in Figure 2c , two major shifted bands were observed with nuclear extracts from AP-2a-positive SB-2 cells (Figure 2c , lane 1), with both bands being supershifted when reacted with anti-AP-2a antibodies (lane 3). In contrast, nuclear extracts from the SW480neo control cells yielded very faint bands for AP-2 binding (lane 4), whereas nuclear extracts from the two AP-2a-transfected clones yielded bands similar to the pattern observed with the SB-2 cells (lanes 5 and 8), with both bands being supershifted To further confirm that the AP-2a in the transfected cells is transcriptionally active, we took advantage of the observation that AP-2 transactivates the metallothionein promoter driven by three AP-2 consensus response elements (Huang et al., 1998) . The reporter constructs were transfected into control or AP-2a-transfected SW480 cells, together with the pB-actin-RL plasmid that served as an internal control for transfection efficiency. Luciferase activity was 20-fold higher in the AP-2a transfectants clones 1 and 2, as compared with the neo-control cells (Figure 2d ). These data demonstrate that the two AP-2a stably transfected clones 1 and 2 expressed high levels of active AP-2a.
Forced expression of AP-2a has been previously shown to result in a transient transcriptional upregulation of p21 WAF1/CIP1 expression and a concomitant cell cycle arrest in SW480 cells (Zeng et al., 1997; Wajapeyee and Somasundaram, 2003) . We have, therefore, examined the growth rate and p21 WAF1/CIP1 expression in the two SW480 clones selected for stable expression did not increase in AP-2a transfected clones as compared with the empty vectortransfected clone (Figure 3b) .
The effect of enforced expression of AP-2 on tumor growth of colon cancer cells in vivo has not been previously investigated. To that end, two clones of SW480 cells expressing functional AP-2a and SW480neo control cells were injected into the cecal wall of nude mice (orthotopic injections), and the mice were sacrificed 60 days later. The results depicted in Table 1 show that transfection with AP-2a completely abolished tumor development by clone 1, while clone 2 formed tumor only in 1 out of 8 mice injected. Mice injected with the neo-control cells formed tumors in all mice injected (Po0.001). In addition, the one tumor developed by clone 2 was significantly smaller than the tumor formed in mice injected with the SW480neo control cells (Table 1) . Hematoxylin and Eosin (H&E) staining of this tumor revealed highly differentiated characteristics (see the crypt-like tissue) (Figure 4b ), and this was significantly different from the tumor tissue obtained from SW480neo cells in which an undifferentiated morphology was observed (Figure 4a ).
Transfection with AP-2a upregulates E-cadherin expression As AP-2a is known to positively regulate the expression of E-cadherin (Batsche et al., 1998; West-Mays et al, 2003; Sumigama et al., 2004) , we next examined the effect of AP-2a transfection on the expression of E-cadherin in SW480 cells. The results depicted in Figure 5a (Western blot) show that although the control SW480neo cells do not express E-cadherin (lane 1), the two AP-2a-transfected clones 1 and 2 express E-cadherin ( Figure 5a , lanes 2 and 3). This effect is owing to a direct effect of AP-2a on the E-cadherin promoter (Figure 5b ). Luciferase activity driven by the E-cadherin promoter was increased by 4-fold in the AP2a-transfected clones as compared with the control cells (Figure 5b) , consistent with the results obtained on the protein levels. The in vivo association of AP-2a with the proximal GC-rich region of E-cadherin promoter known to bind AP-2 was confirmed by the ChIP assay. In SW480neo cells, no AP-2a binding was detected (Figure 5c ). In contrast, in both transfected clones, the AP-2a binding to this promoter region was observed. Collectively, our data indicate that loss of AP-2a may be responsible for the loss of E-cadherin expression in colon cancer cells, thus contributing to their tumorigenicity. Waf1/Cip1 expression in SW480 AP-2a-transfected clones and SW480neo control cells. Blot was stripped and re-probed with anti-a-actin antibody for loading control. Mice were injected with 1 Â 10 6 cells into the cecum. Tumor incidence and size were recorded 60 days later. To examine the effect of AP-2a on MMP-9 transcription, we next analyzed the promoter activity of MMP-9 in the AP-2a-transfected clones 1 and 2. Consistent with a decreased MMP-9 expression in the transfected cells, the luciferase activity driven by the MMP-9 promoter was decreased by 6-and 14-fold in clones 1 and 2, respectively, as compared with the control cells, which were given the value of 1 (Figure 6c ).
Basal as well as induced activity of the human MMP-9 promoter is known to be regulated by several cis-acting elements, including motifs that bind AP-1, nuclear factor-kappa B (NF-kB) and Sp-1 transcription factors (Sato and Seiki, 1993; Gum et al., 1996) . Our sequence analysis revealed an Sp-1 binding site/GC-box in the MMP-9 promoter (À563 to À558 relative to the start site) that could serve as a potential binding site for AP-2 (Figure 6d ). This region of the MMP-9 promoter is surrounded by previously described distal AP-1 consensus site (À533 to À527), and NF-kB-binding element (À600 to À591). We have hypothesized that downregulation of MMP-9 promoter activity after AP-2a re-expression in SW480 cells was due to a direct AP-2a binding and, possibly, changes in the recruitment of other transcription factors. The in vivo association of AP-2a with this region of the MMP-9 promoter was therefore investigated by the ChIP assay. In SW480neo cells, no AP-2a binding was detected (Figure 6e ). In contrast, in both transfected clones, AP-2a was found to bind to this promoter region. Simultaneously, a decrease in Sp-1 binding was observed in AP-2a transfected clones as compared with SW480neo cells (Figure 6e ). These data suggest that AP-2a regulates MMP-9 promoter activity by competing with Sp-1 for binding to the GC-rich sequences. 
Transfection with AP-2a inhibits the in vitro invasive properties of SW480 cells
As re-expression of AP-2a in SW480 caused upregulation of E-cadherin and downregulation of MMP-9, we next investigated whether the re-expression of AP-2a was sufficient to decrease the in vitro ability of SW480 cells to invade through filters coated with Matrigelreconstituted basement membrane matrix. The results demonstrate that AP-2a indeed significantly reduced the invasive capacity of SW480 cells by 10-or 8.8-folds in clones 1 and 2, respectively, as compared with control SW480neo cells (Po0.01) (Figure 7) .
Effect of AP-2a knockdown in KM12C cells
To further confirm the role of AP-2a in tumor growth and invasiveness of colon cancer cells, we next attempted to silence its expression by siRNA in the AP-2a-positive KM12C cells, and subsequently analyze the expression of E-cadherin and MMP-9. Figure 8a shows that transfection of KM12C cells with AP-2a-specific siRNA resulted in a 65% loss of AP-2a protein expression (KM12C-AP2-aKD cells) as compared with control parental and Western blot analyses further demonstrated that loss of AP-2a in KM12C cells resulted in a decrease in E-cadherin expression by 40% (Figure 8b) , and a concomitant increase in expression of MMP-9 protein by approximately 30% (Figure 8c ). This demonstrates that constitutive AP-2a expression is at least in part responsible for maintaining high levels of E-cadherin and low levels of MMP-9 expression in colon cancer cells.
We further pursued to verify whether AP-2a knockdown in KM12C cells would stimulate their invasive properties. To that end, KM12C cells transfected with AP-2a siRNA, non-targeting siRNA or control parental cells were allowed to invade through Matrigel-reconstituted basement membrane matrix. AP-2a knockdown resulted in an 11-fold increase in cell invasion as compared with control cells (Figure 8d) .
Discussion
This investigation provides evidence that the progression of colon cancer is associated with loss of AP-2a expression. We demonstrate for the first time that reintroduction of AP-2a into colon cancer cells affects their tumorigenicity in an orthotopic model in vivo. In addition, our analysis of MMP-9 promoter provides the first evidence that human MMP-9 promoter is regulated by AP-2a. 
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Somasundaram, 2003). We did not observe any change in p21
Waf1/Cip1 expression in the AP-2a-transfected SW480 clones, which can explain our ability to maintain the cells in cultures and subsequent in vivo experiments. The inhibition in the tumorigenicity of the colon cancer cells in vivo could be explained by the effect of AP-2a on the regulation of E-cadherin and MMP-9 expression. We found that transfection of AP-2a into the AP-2-negative SW480 cells resulted in the expression of E-cadherin and downregulation in the expression and activity of MMP-9. On the other hand, targeting constitutive expression of AP-2a in the AP-2-positive KM12C colon cancer cells with siRNA resulted in an increase in MMP-9 and downregulation of E-cadherin expression.
Our data further demonstrate that AP-2a positively regulates E-cadherin expression in colon cancer cells by direct interaction with the proximal region of E-cadherin promoter. Furthermore, we demonstrate that AP-2a negatively regulates MMP-9 gene expression and activity via a direct binding to its promoter and interference with the binding of Sp-1 and AP-1 transcription factors. We have previously shown that AP-2a competes with Sp-1 for the occupancy on the promoter of PAR-1 and that an increase in the AP-2a/ Sp1 ratio leads to negative regulation of PAR-1 promoter activity in melanoma cells . Intriguingly, in SW480 colon cancer cells, AP-2a re-expression also changed the recruitment of Fos/Jun family transcription factors to the AP-1 consensus site located 33 bp downstream of the GC-box/Sp-1 binding site. Disappearance of Fos-like proteins was observed in parallel with a gain in binding of the Jun family proteins, particularly Jun B. The significance as well as the exact mechanism of this effect are unclear and require a detailed investigation. Our preliminary findings also indicate that AP-2a-transfected cells express slightly lower levels of c-Fos, which could explain at least in part a decrease in Fos binding to the MMP-9 promoter (data not shown). In addition, analysis of the MMP-9 promoter sequence suggests the existence of another AP-2-like binding site, which is located immediately upstream of the GC-box and partly overlaps with an NF-kB binding.
In addition to a direct regulation of expression of E-cadherin and MMP-9, AP-2a could potentially act as a regulator of the fine-tuning in the counter-activation between E-cadherin and MMPs as it has been recently reported that inhibition of MMPs prevented cadherin ectodomain cleavage resulting in the stabilization of cadherin-mediated cell-to-cell interactions (Ho et al., 2001) . Overall, our data suggest that induction of AP-2a expression including introducing the AP-2a gene into cancer cells might offer new therapeutic strategy for colon cancer. The identification of other AP-2a target genes deregulated as a result of loss of AP-2a in colon cancer may uncover additional molecular changes driving colon cancer progression. 
Materials and methods

Cell lines
The colon cancer cell lines SW480, SW620, KM12C, KM12L4A, KM12SM, the melanoma cell line SB-2 and the breast cancer cell line MCF-7 and their biological properties were described previously (Morikawa et al., 1998; .
Semiquantitative RT-PCR RNA extraction and RT-PCR analysis for AP-2a and GAPDH were performed as described previously .
Antibodies
Antibodies to AP-2a (C18), which were used in Western blot analyses, were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-E-cadherin, anti-MMP-9 and anti-p21 
Western blotting
Western blot analysis was performed as described previously (Melnikova et al., 2006) .
Expression constructs and stable transfections
The pcDNA3.1-AP-2a construct was used for stable transfection and was created by cloning the AP-2a cDNA into the EcoR1 site of pcDNA3.1 (Invitrogen Inc., Carlsbad, CA, USA), as described previously . The pcDNA3.1-AP-2a or control pcDNA3.1 vector were transfected into SW480 cells, and stable transfectants were selected in the presence of 1 mg/ml of G-418 (Invitrogen, Carlsbad, CA, USA).
EMSA EMSA for AP-2 was performed as described previously (Huang et al. 1998) Reporter constructs and luciferase assay The 3xAP-2a-Luc luciferase reporter construct contains three AP-2 consensus elements from the human metallothionein gene IIA ligated in front of a minimal thymidine kinase promoter, as described previously (Huang et al., 1998) . The E-cadherin Luc promoter construct contains the minimal E-cadherin promoter (À179-þ 41-Luc) (Comijin et al., 2001) . The MMP-9 luciferase construct containing full length MMP-9 promoter was described previously (Yan et al., 2004) . The dual luciferase reporter assay was performed as described previously (Melnikova et al., 2006) . Zymography MMP-9 activity was determined on substrate-impregnated gels as described earlier (Huang et al., 2002) .
ChIP
The ChIP assay was performed using the reagents provided in a ChIP-IT kit obtained from Active Motif (Carlsbad, CA, USA). A 227-bp fragment spanning À731 to À504 region of the MMP-9 promoter was amplified by PCR using primer sequences 5 0 -AGT GGT AAG ACA TTT GCC CGA GGT-3 0 and 5 0 -TTT CCC TCC CTG ACA GCC TTC TTT-3 0 . A 165-bp fragment spanning À171 to À6 region of the E-cadherin promoter was amplified by PCR using primer sequences 5 0 -TAG AGG GTC ACC GCG TCT ATG-3 0 and 5 0 -GGG TCC GTG GCT GCA GCC AGG-3 0 . The PCR was subjected to initial denaturation step (4 min at 961C), followed by 27 cycles of denaturation (1 min at 941C), annealing (1 min at 60 or 681C for E-cadherin and MMP-9 respectively) and extension (1 min at 721C). Then reaction was subjected to a final extension time of 5 min at 721C. PCR products were analyzed on a 2% agarose gel containing ethidium bromide.
Animals and orthotopic implantation of tumor cells
For orthotopic implantations, 8-10 week old mice were anesthetized by intraperitoneal injection of Nembutal. Low abdominal incisions were performed, and a suspension of 1 Â 10 6 viable cells diluted in 75 ml of Hanks' buffer saline solution were injected into the cecal wall. Mice were necropsied 60 days following cell injection. Tumor presence was noted by gross histology. Tumors were measured and immediately frozen, and then processed for H&E staining.
Tissue H&E staining Four-micrometer sections of frozen sections of tumors were used for H&E staining. Images were acquired using a Zeiss photomicroscope (Carl Zeiss Inc., Thornwood, NY, USA) connected to a Sony Model DXC-960 MD Camera (Sony Corp., Tokyo, Japan).
Invasion assay
Matrigel invasion assays were performed as described previously (Huang et al., 2002) .
AP-2a-specific siRNA AP-2a-specific siRNA was obtained from Dharmacon (Lafayette, CO, USA) as ON-TARGETplust SMARTpool reagent, which contains a pool of four different doublestranded RNA oligonucleotides directed against AP-2a (Cat# L-006348-00). Non-targeting siRNA was obtained from Dharmacon as ON-TARGETplust siCONTROL doublestranded RNA oligonucleotides (Cat# D-001810-01). KM12C cells were transfected in suspension in six-well plates using Lipofectamine 2000 reagent (Invitrogen, Inc.) with 0.6 nmol siRNA. Protein lysates were collected 72 h post-transfection.
Statistical Analysis
The Student's t-test was used to analyze statistical significance at the 95% confidence interval for the in vitro studies. The in vivo data were analyzed by the Mann-Whitney test.
Abbreviations AP-2a, activator protein-2a; EMSA, electrophoretic mobility shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP-9, metalloproteinase-9; ChIP, chromatin immunoprecipitation.
